Analysts Raise Targets on Affymetrix's Stock but Remain Cautious

Though Affy's revenues and EPS beat estimates, analysts remained cautious about the firm.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.